Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Summary

This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5

Eligibility

Inclusion Criteria:

* Provided informed consent to participate in the study;
* Aged 18 years or older;
* Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
* Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;

Exclusion Criteria:

* Patients who are at LLDAS5 at the time of study entry;
* Previous exposure to anifrolumab;
* Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy \[mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids\], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
* Currently participating in any interventional clinical trial with an investigational product;
* Inability to understand and sign the informed consent and to fill in patient questionnaires

Conditions2

Interventions1

Related trials

• Anifrolumab Malignancy and Serious Infections Study — AstraZeneca
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus — AstraZeneca
• The Anifrolumab PRIM Program — AstraZeneca
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — AstraZeneca
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — AstraZeneca
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — AstraZeneca
• Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users — AstraZeneca

Browse More Trials